Treat-to-target strategies are used in several chronic diseases to improve outcomes. Treatment goals have also been suggested for psoriasis, but there is currently no consensus on targets, and guidance is needed to implement this strategy in clinical practice. The project ‘Treat to Target Italia’ was launched by a scientific board (SB) of 10 psoriasis experts to generate expert consensus recommendations.

Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis. Consensus recommendations / Gisondi, P; Talamonti, M; Chiricozzi, A; Piaserico, S; Amerio, P; Balato, A; Bardazzi, F; Calzavara Pinton, P; Campanati, A; Cattaneo, A; Dapavo, P; De Simone, C; Dini, V; Fargnoli, Mc; Flori, Ml; Galluzzo, M; Guarneri, C; Lasagni, C; Loconsole, F; Lo Schiavo, A; Malagoli, P; Malara, G; Mercuri, Sr; Musumeci, Ml; Naldi, L; Papini, M; Parodi, A; Potenza, C; Prignano, F; Rongioletti, F; Stingeni, L; Tiberio, R; Venturini, M; Bianchi, L; Costanzo, A; Cusano, F; Girolomoni, G; Offidani, Am; Peris, K.. - 11:1(2021), pp. 235-252. [10.1007/s13555-020-00475-8]

Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis. Consensus recommendations

Potenza C;
2021

Abstract

Treat-to-target strategies are used in several chronic diseases to improve outcomes. Treatment goals have also been suggested for psoriasis, but there is currently no consensus on targets, and guidance is needed to implement this strategy in clinical practice. The project ‘Treat to Target Italia’ was launched by a scientific board (SB) of 10 psoriasis experts to generate expert consensus recommendations.
2021
consensus; plaque psoriasis; quality of life; systemic inflammation; treatto-target
01 Pubblicazione su rivista::01a Articolo in rivista
Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis. Consensus recommendations / Gisondi, P; Talamonti, M; Chiricozzi, A; Piaserico, S; Amerio, P; Balato, A; Bardazzi, F; Calzavara Pinton, P; Campanati, A; Cattaneo, A; Dapavo, P; De Simone, C; Dini, V; Fargnoli, Mc; Flori, Ml; Galluzzo, M; Guarneri, C; Lasagni, C; Loconsole, F; Lo Schiavo, A; Malagoli, P; Malara, G; Mercuri, Sr; Musumeci, Ml; Naldi, L; Papini, M; Parodi, A; Potenza, C; Prignano, F; Rongioletti, F; Stingeni, L; Tiberio, R; Venturini, M; Bianchi, L; Costanzo, A; Cusano, F; Girolomoni, G; Offidani, Am; Peris, K.. - 11:1(2021), pp. 235-252. [10.1007/s13555-020-00475-8]
File allegati a questo prodotto
File Dimensione Formato  
Gisondi_Treat-to-target_2021t.pdf

accesso aperto

Note: https://link.springer.com/article/10.1007/s13555-020-00475-8
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 413.87 kB
Formato Adobe PDF
413.87 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1570668
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 40
  • ???jsp.display-item.citation.isi??? 34
social impact